Expert Review of Pharmacoeconomics & Outcomes Research

Papers
(The H4-Index of Expert Review of Pharmacoeconomics & Outcomes Research is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications48
Distinguishing features in the assessment of mHealth apps38
Real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic37
Health-related quality of life in patients with chronic kidney disease27
Tools to assess the quality of life in patients with Parkinson’s disease: a systematic review27
First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China26
Will the Markov model and partitioned survival model lead to different results? A review of recent economic evidence of cancer treatments23
Evaluation instruments for executive functions in children and adolescents: a systematic review20
Outcome measures for physical fatigue in individuals with multiple sclerosis: a systematic review18
A comparison of measurement properties between UK SF-6D and English EQ-5D-5L and Thai EQ-5D-5L value sets in general Thai population17
Micro-costing diagnostics in oncology: from single-gene testing to whole- genome sequencing17
Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease16
Prevalence of chronic respiratory morbidity, length of stay, inpatient readmissions, and costs among extremely preterm infants with bronchopulmonary dysplasia16
Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China15
Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study15
0.044528961181641